Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?

Clicks: 391
ID: 12880
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #2 of 4 articles by views in clinical and applied thrombosis/hemostasis : official journal of the international academy of clinical and applied thrombosis/hemostasis

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.
Reference Key
ramacciottidirectclinical Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ramacciotti, Eduardo;Agati, Leandro B;Caffaro, Roberto Augusto;Volpiani, Giuliano G;Lopes, Renato D;Comerota, Anthony J;Fareed, Jawed;
Journal clinical and applied thrombosis/hemostasis : official journal of the international academy of clinical and applied thrombosis/hemostasis
Year Year not found
DOI
10.1177/1076029619856433
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.